Search

Cancer immunotherapy has ushered in a transformative era in oncology, offering unprecedented promise and opportunities. Despite its remarkable breakthroughs, the field continues to grapple with the persistent challenge of treatment resistance. This resistance not only undermines the widespread efficacy of these pioneering treatments, but also underscores the pressing need for further research. Our exploration into the intricate realm of cancer immunotherapy resistance reveals various mechanisms at play, from primary and secondary resistance to the significant impact of genetic and epigenetic factors, as well as the crucial role of the tumor microenvironment (TME). Furthermore, we stress the importance of devising innovative strategies to counteract this resistance, such as employing combination therapies, tailoring immune checkpoints, and implementing real-time monitoring. By championing these state-of-the-art methods, we anticipate a paradigm that blends personalized healthcare with improved treatment options and is firmly committed to patient welfare. Through a comprehensive and multifaceted approach, we strive to tackle the challenges of resistance, aspiring to elevate cancer immunotherapy as a beacon of hope for patients around the world.

Breast cancer is a heterogeneous disease characterized by distinct molecular subtypes, varied prognoses, and differential treatment responses. Understanding the molecular landscape and identifying therapeutic targets, such as trophoblast cell-surface antigen 2 (TROP2), is vital. TROP2 is notably overexpressed in breast cancer, playing a significant role in tumor growth, invasion, metastasis, and treatment resistance. While significant progress has been made in targeting TROP2 in breast cancer, several challenges and knowledge gaps remain. These challenges include the heterogeneity of TROP2 expression within breast cancer subtypes, resistance to its targeted therapies, potential off-target effects, limited therapeutic agents, and identifying optimal combination treatments. Integrating findings from clinical trials into clinical practice further complicates the landscape. This review article delves deep into TROP2 in breast cancer, highlighting its expression patterns, clinical implications, and therapeutic advancements. By understanding the role of TROP2, we can pave the way for personalized treatments, and transform the landscape of breast cancer care.

Confirmed SARS-CoV-2-caused disease (COVID-19) cases have reached 275.65 million worldwide. Although the majority of COVID-19 patients present mild to moderate symptoms, some have severe complications including death. We first reviewed the pathogenesis on ACE2, a binding receptor of SARS-CoV-2 expressed in multiple organs, and prevalent multinucleate syncytia in the lung tissues of COVID-19 patients. Then, we evaluated the pathological, immunological changes and sequelae in the major organs. Finally, we reviewed the immunological memory after SARS-CoV-2 infection and vaccination. The binding of SARS-Cov-2 to ACE2 receptor results in reduced ACE2 protein levels, which may lead to elevated susceptibility to inflammation, cell death, organ failure, and potentially severe illness. These damages increase the risk of health problems over a long period, which result in many complications. The complications in multiple organs lead to the increased risk of long-term health problems that require additional attention. A multidisciplinary care team is necessary for further management and recovery of the COVID-19 survivors. Many COVID-19 patients will probably make antibodies against SARS-CoV-2 virus for most of their lives, and the immunity against reinfection would last for 3-61 months.

Neoadjuvant chemotherapy (NACT) was developed with the aims of shrinking tumors or stopping cancer cells from spreading before surgery. Unfortunately, not all breast cancer patients will benefit from NACT, and thus, patients must weigh the risks and benefits of treatment prior to the initiation of therapy. Currently, the data for predicting the efficacy of NACT is limited. Molecular testing, such as Oncotype DX, MammaPrint, and Curebest 95GC, have been developed to assist which breast cancer patients will benefit from the treatment. Patients with an increased level of Human Leukocyte Antigen-DR isotype, tumor-infiltrating lymphocytes, Fizzy-related protein homolog, and a decreased level of tumor-associated macrophages appear to benefit most from NACT.

BACKGROUND: Calcium phosphate cements (CPCs) are biocompatible materials that have been evaluated as scaffolds in bone tissue engineering. At present, the stem cell density of inoculation on CPC scaffold varies. OBJECTIVE: The aim of this study is to analyze the effect of seeding densities on cell growth and osteogenic differentiation of bone marrow mesenchymal stem cells (BMMSCs) on a calcium phosphate cements (CPCs) scaffold. METHODS: BMMSCs derived from minipigs were seeded onto a CPC scaffold at three densities [1 million/mL (1M), 5 million/mL (5M) and 25 million/mL 25M)], and cultured for osteogenic induction for 1, 4 and 8 days. RESULTS: Well adhered and extended BMMSCs on the CPC scaffold showed significantly different proliferation rates within each seeding density group at different time points (P < 0.05). The number of live cells per unit area in 1M, 5M and 25M increased by 3.5, 3.9 and 2.5 folds respectively. The expression of ALP peaked at 4 days post inoculation with the fold-change being 2.6 and 2.8 times higher in 5M and 25M respectively as compared to 1M. The expression levels of OC, Coll-1 and Runx-2 peaked at 8 days post inoculation. CONCLUSIONS: An optimal seeding density may be more conducive for cell proliferation, differentiation, and extracellular matrix synthesis on scaffolds. We suggest the optimal seeding density should be 5 million/mL. [ABSTRACT FROM AUTHOR]

Near-infrared (NIR) phosphor-converted light emitting diode (pc-LED) light sources have broad application prospects in environmental science, biomedical and plant growth fields. However, NIR phosphors still suffer from narrowband emission and low thermal stability. Here, we prepared a novel Lu2CaMg2−xSi3O12:xCr3+ (LCMS:xCr3+, x = 0.005–0.06) phosphor with broadband emission by a high-temperature solid state reaction. Under excitation at 450 nm, the emission spectrum of the LCMS:0.05Cr3+ phosphor shows a broadband emission in the range of 650–1000 nm with a large full width at half maximum (FWHM) of 125 nm and an R-line emission of 692 nm. In addition, the LCMS:0.05Cr3+ phosphor has good thermal stability and can maintain 70% emission intensity at 150 °C relative to that at room temperature. The LCMS:0.05Cr3+ phosphor exhibits a high internal quantum efficiency (IQE) of ∼76%. Using this phosphor, a NIR pc-LED with photoelectric efficiencies of 14.8% at 100 mA and 6.0% at 320 mA and NIR output powers of 59.5 mW at 100 mA and 181.0 mW at 320 mA was obtained. The broadband LCMS:0.05Cr3+ phosphor with a NIR emission peaked at 750 nm can serve as a light source for plant cultivation and has superior application prospects in the agriculture field. [ABSTRACT FROM AUTHOR]

An oxyfluoride red phosphor Cs2MoO2F4:Mn4+ was synthesized via a facile co-precipitation route with a certain molecular ratio of CsF and MoO3. X-ray diffraction analysis and its Rietveld refinement reveal that Cs2MoO2F4:Mn4+ crystallized in an orthorhombic structure with the Amam (63) space group. Upon blue light excitation, Cs2MoO2F4:Mn4+ exhibits a series of sharp red emission lines around ∼634 nm and the zero-phonon line (ZPL) is visible at 619 nm. The optimal doping amount of Mn4+ in Cs2MoO2F4 is 1.12%, and the decay curves show a good fit with the single exponential decay model. The fluorescence lifetime of the synthesized phosphors is relatively short and calculated as 3.18 to 2.46 ms, the Mn4+ ions in Cs2MoO2F4 experience a strong crystal field strength with a Dq/B of ∼4.87, and the distinct nephelauxetic ratio β1 is determined to be ∼1.0226. The thermal quenching mechanism of Mn4+ was also studied. Furthermore, by using the as-synthesized Cs2MoO2F4:Mn4+ phosphor as a red component and β-SiALON as a green light component, a WLED was fabricated with a high luminous efficacy of 114.70 lm·W−1 and wide color gamut of 109.1% of the National Television Standard Committee (NTSC) value. Hence, the Cs2MoO2F4:Mn4+ phosphor with a short fluorescence lifetime could potentially be an efficient red compensator for application in rapid-response backlight displays. [ABSTRACT FROM AUTHOR]

A palladium-catalyzed highly C‒S-selective Stille cross-coupling between aryl thianthrenium salts and tri- or tetrasubstituted alkenyl stannanes is described. Herein, critical challenges including site- and chemoselectivity control are well addressed through C‒H thianthrenation and C‒S alkenylation, thereby providing an expedient access to stereodefined tri- and tetrasubstituted alkenes in a stereoretentive fashion. Indeed, the palladium-catalyzed Stille-alkenylation of poly(pseudo)halogenated arenes displays privileged capability to differentiate C‒S over C‒I, C‒Br, C‒Cl bonds, as well as oxygen-based triflates (C‒OTf), tosylates (C‒OTs), carbamates and sulfamates under mild reaction conditions. Sequential and multiple cross-couplings via selective C‒X functionalization should be widely applicable for increasing functional molecular complexity. Modular installation of stereospecific alkene motifs into pharmaceuticals illustrated the synthetic application of the present protocol in drug discovery., (© 2024 Wiley‐VCH GmbH.)

Near-infrared (NIR) phosphor-converted light emitting diode (pc-LED) light sources have broad application prospects in environmental science, biomedical and plant growth fields. However, NIR phosphors still suffer from narrowband emission and low thermal stability. Here, we prepared a novel Lu2CaMg2-xSi3O12:xCr3+ (LCMS:xCr3+, x = 0.005-0.06) phosphor with broadband emission by a high-temperature solid state reaction. Under excitation at 450 nm, the emission spectrum of the LCMS:0.05Cr3+ phosphor shows a broadband emission in the range of 650-1000 nm with a large full width at half maximum (FWHM) of 125 nm and an R-line emission of 692 nm. In addition, the LCMS:0.05Cr3+ phosphor has good thermal stability and can maintain 70% emission intensity at 150 °C relative to that at room temperature. The LCMS:0.05Cr3+ phosphor exhibits a high internal quantum efficiency (IQE) of ∼76%. Using this phosphor, a NIR pc-LED with photoelectric efficiencies of 14.8% at 100 mA and 6.0% at 320 mA and NIR output powers of 59.5 mW at 100 mA and 181.0 mW at 320 mA was obtained. The broadband LCMS:0.05Cr3+ phosphor with a NIR emission peaked at 750 nm can serve as a light source for plant cultivation and has superior application prospects in the agriculture field.

An oxyfluoride red phosphor Cs 2 MoO 2 F 4 :Mn 4+ was synthesized via a facile co-precipitation route with a certain molecular ratio of CsF and MoO 3 . X-ray diffraction analysis and its Rietveld refinement reveal that Cs 2 MoO 2 F 4 :Mn 4+ crystallized in an orthorhombic structure with the Amam (63) space group. Upon blue light excitation, Cs 2 MoO 2 F 4 :Mn 4+ exhibits a series of sharp red emission lines around ∼634 nm and the zero-phonon line (ZPL) is visible at 619 nm. The optimal doping amount of Mn 4+ in Cs 2 MoO 2 F 4 is 1.12%, and the decay curves show a good fit with the single exponential decay model. The fluorescence lifetime of the synthesized phosphors is relatively short and calculated as 3.18 to 2.46 ms, the Mn 4+ ions in Cs 2 MoO 2 F 4 experience a strong crystal field strength with a Dq/B of ∼4.87, and the distinct nephelauxetic ratio β 1 is determined to be ∼1.0226. The thermal quenching mechanism of Mn 4+ was also studied. Furthermore, by using the as-synthesized Cs 2 MoO 2 F 4 :Mn 4+ phosphor as a red component and β-SiALON as a green light component, a WLED was fabricated with a high luminous efficacy of 114.70 lm·W -1 and wide color gamut of 109.1% of the National Television Standard Committee (NTSC) value. Hence, the Cs 2 MoO 2 F 4 :Mn 4+ phosphor with a short fluorescence lifetime could potentially be an efficient red compensator for application in rapid-response backlight displays.